scholarly journals Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing

2014 ◽  
Vol 145 (3) ◽  
pp. 707-714 ◽  
Author(s):  
Priyanka Sharma ◽  
Jennifer R. Klemp ◽  
Bruce F. Kimler ◽  
Jonathan D. Mahnken ◽  
Larry J. Geier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cancer Registry ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Brca Mutation ◽  
Cancer Syndrome ◽  
Germline Brca Mutation ◽  
Breast Cancer Registry

scholarly journals Determinants of Prognosis in Triple-Negative Breast Cancer: Report from a Large Breast Cancer Registry

2021 ◽  
Vol 24 (4) ◽  
pp. 280-288
Author(s):  
Sedigheh Tahmasebi ◽  
Ali Mosa Jafar Almayali ◽  
Peyman Arasteh ◽  
Majid Akrami ◽  
Vahid Zangouri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Registry ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Large Breast ◽  
Breast Cancer Registry

scholarly journals A review of current progress in triple-negative breast cancer therapy

Open Medicine ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. 1143-1149
Author(s):  
Meiying Shen ◽  
Huawen Pan ◽  
Yuxia Chen ◽  
Yu Hang Xu ◽  
Weixiong Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Brca Mutation ◽  
Complete Response ◽  
Parp Inhibitors ◽  
The Past ◽  
Germline Brca Mutation ◽  
Aggressive Subtype

AbstractTriple-negative breast cancer (TNBC) is a particularly aggressive subtype known for its extremely high drug resistance, progression, poor prognosis, and lack of clear therapeutic targets. Researchers are aiming to advance TNBC treatment worldwide. In the past 2–3 years, more positive results have emerged in the clinical research on TNBC treatment. Based on the results, several impressive drugs have been approved to benefit patients with TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation-associated breast cancer (gBRCAm-BC) and immunotherapy using the checkpoint inhibitor atezolizumab in combination with nab-paclitaxel for programmed cell death-ligand 1-positive (PD-L1+) advanced TNBC. Although neoadjuvant therapy has focused on combinations of systemic agents to optimize pathologically complete response, metastatic TNBC still has a poor prognosis. Innovative multidrug combination systemic therapies based on neoadjuvants and adjuvants have led to significant improvements in outcomes, particularly over the past decade.

scholarly journals Triple-negative breast cancer and BRCA mutation: looking at the future

2016 ◽  
Vol 27 ◽  
pp. iv66
Author(s):  
Z. Ballatore ◽  
M. Pistelli ◽  
R. Bracci ◽  
F. Bianchi ◽  
E. Maccaroni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Brca Mutation ◽  
The Future

scholarly journals PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms

2019 ◽  
Vol 7 ◽  
pp. 232470961986498 ◽  
Author(s):  
Trevanne Matthews Hew ◽  
Lara Zuberi
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Brca Mutation ◽  
Parp Inhibitor ◽  
Parp Inhibitors ◽  
Management Options ◽  
Federal Drug Administration ◽  
Platinum Based Chemotherapy ◽  
Metastatic Setting

Triple-negative breast cancer (TNBC) accounts for 20% of breast cancers diagnosed worldwide. This subtype of breast cancer tends to behave more aggressively, and unlike other breast cancer subtypes, there are no standard targeted treatments for most patients. However, up to 20% of patients with TNBC harbor a breast cancer gene (BRCA) mutation, particularly in BRCA1. For patients who carry this gene mutation, this opens the door for new management options by the use of newer agents such as polyadenosine diphosphate-ribose polymerase (PARP) inhibitors in the metastatic setting. Given that this is uncommon and that PARP inhibitors have only recently received Federal Drug Administration approval, the experience with these drugs is relatively new. In this article, we present a case of a patient treated in this setting with olaparib who developed an unanticipated side effect as a result of the high efficacy of the drug.

scholarly journals Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

2016 ◽  
Vol 22 (12) ◽  
pp. 2855-2864 ◽  
Author(s):  
Eve T. Rodler ◽  
Brenda F. Kurland ◽  
Melissa Griffin ◽  
Julie R. Gralow ◽  
Peggy Porter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase I ◽  
Triple Negative Breast Cancer ◽  
Phase I Study ◽  
Triple Negative ◽  
Brca Mutation

Demographic variation of Ki67 and its relation with prognosis in triple-negative breast cancer: A single-center pilot project.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11539-e11539
Author(s):  
Mashrafi Ahmed ◽  
Tahmina Begum
Keyword(s):  
Breast Cancer ◽  
Cancer Registry ◽  
Triple Negative Breast Cancer ◽  
Large Scale ◽  
Triple Negative ◽  
Statistical Significance ◽  
Retrospective Chart Review ◽  
Pilot Project ◽  
Single Center ◽  
Ki 67

e11539 Background: Ki-67 is a proliferation marker expressed during cell cycle. ASCO does not recommend this biomarker to be done routinely in breast cancer. As triple negative breast cancer lacks all the ASCO recommended biomarkers (estrogen, progesterone and HER-2 gene), non-recommended markers may carry significant prognostic value in different demographic population. Methods: A retrospective chart review was conducted on patients who were diagnosed with triple negative breast cancer at Saint Joseph Hospital, Chicago from 2005 to 2010. We analyzed the data for Ki67 value among age group, race, menstrual status, tumor histology, stage, treatment given and outcome of the treatment. The data was obtained from medical record, cancer registry and department of pathology. Results: Only 35 cases were found retrospectively. The mean age was 55.6 year. Nearly 47% were African American, 38% White and rest was other races. Most of the cases (71%) were post-menopausal. The average follow-up was 214 days with nearly 62% patients remained disease free, 21% suffered from relapse but alive and 18% died from relapse. The analysis of data is presented here in tabulated form. Conclusions: In our study, we could not reach to statistical significance mostly due to small size of the population. Being a rare subtype of breast cancer, a single center data analysis is not sufficient. This pilot study will encourage us to go for a large scale study involving multi-center or cancer registry data of the state of Illinois. [Table: see text] [Table: see text] [Table: see text] [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document